ArticleFrontiers in psychiatry2022

Rivastigmine for ECT-induced cognitive adverse effects in late life depression (RECALL study): A multicenter, randomized, double blind, placebo-controlled, cross-over trial in patients with depression aged 55 years or older: Rationale, objectives and methods.

Marieke J Henstra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.